Apontis Pharma AG Cash Flow Conversion Efficiency

Latest as of June 2025: -0.061x

Apontis Pharma AG cash flow conversion efficiency. Based on the latest financial reports, Apontis Pharma AG (APPH) has a cash flow conversion efficiency ratio of -0.061x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.94 Million ≈ $-2.27 Million USD) by net assets (€31.62 Million ≈ $36.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Apontis Pharma AG (2019–2024)

Cash flow conversion efficiency of Apontis Pharma AG from 2019 to 2024. This chart illustrates how Apontis Pharma AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Apontis Pharma AG share price for real-time trading data and today's change.

Apontis Pharma AG Cash Flow Conversion Ratio Explained

Apontis Pharma AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Apontis Pharma AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Apontis Pharma AG ranked by their cash flow conversion efficiency. Also see how much is Apontis Pharma AG worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Cettire Ltd AU:CTT	-1.619x
Reworld Media PA:ALREW	0.128x
Deleum Bhd KLSE:5132	0.116x
Ufuk Yatirim Yonetim Ve Gayrimenkul AS IS:UFUK	0.000x
Purit Co. Ltd. KQ:445180	0.022x
Melnick Even Desenvolvimento Imobiliário S.A SA:MELK3	-0.002x
Gan Ltd NASDAQ:GAN	-0.074x
Applied BioCode TW:6598	-0.029x

Annual Cash Flow Conversion Efficiency for Apontis Pharma AG (2019–2024)

The table below shows the annual cash flow conversion efficiency of Apontis Pharma AG from 2019 to 2024. Review APPH free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€31.02 Million ≈ $36.26 Million	€-2.90 Million ≈ $-3.39 Million	-0.094x	+77.54%
2023-12-31	€30.26 Million ≈ $35.38 Million	€-12.60 Million ≈ $-14.73 Million	-0.416x	-257.05%
2022-12-31	€41.57 Million ≈ $48.60 Million	€11.02 Million ≈ $12.88 Million	0.265x	+214.37%
2021-12-31	€40.71 Million ≈ $47.60 Million	€3.43 Million ≈ $4.01 Million	0.084x	-79.90%
2020-12-31	€3.46 Million ≈ $4.04 Million	€1.45 Million ≈ $1.70 Million	0.420x	+917.97%
2019-12-31	€4.64 Million ≈ $5.43 Million	€-238.07K ≈ $-278.33K	-0.051x	--

About Apontis Pharma AG

XETRA:APPH Germany Drug Manufacturers - Specialty & Generic

Market Cap

$107.13 Million

€91.63 Million EUR

Market Cap Rank

#19350 Global

#1778 in Germany

Share Price

€11.00

Change (1 day)

+0.00%

52-Week Range

€10.75 - €11.05

All Time High

€26.90